Treatment of Hepatocellular Carcinoma (HCC) During the COVID-19 Outbreak: The Working Group Report of JAMTT-HCC

Hepatol Res. 2020 Jun 24. doi: 10.1111/hepr.13541. Online ahead of print.

Abstract

This contingency guide was formulated on the premise that delivering standard treatment for hepatocellular carcinoma (HCC) has come under strain due to the COVID-19 pandemic. Measures required are likely to vary largely across regions and individual institutions, depending on the level of the strain imposed by the pandemic (e.g., number of inpatients infected with COVID-19 and the availability of resources, including personal protective equipment and inpatient beds). Also, models suggest that second and third waves of COVID-19 will occur before effective vaccines and medicines become widely available in Japan (expected time, 2-3 years). This guide should serve as a good reference for best practices in the management of HCC in light of the possible risk of impending collapse of the healthcare system due to a surge in COVID-19 infections.

Keywords: COVID-19; JAMTT-HCC; hepatocellular carcinoma liver dysfunction.